Anti-CD19 CAR T cell therapy was used in a 60-year-old man with diffuse cutaneous systemic sclerosis who had lung and myocardial fibrosis, pulmonary arterial hypertension, Raynaud’s phenomenon, and arthritis (127). Here, CD19 is linked to arthritic joint disease.